Eurazeo (FR:RF) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kurma Partners has announced the first close at EUR 140 million for its new Biofund IV, with a target of EUR 250 million and plans to make 16 to 20 new investments in innovative therapeutics. The fund, which has already completed three investments, continues Kurma’s strategy of collaborating with academic and industry professionals to foster Europe’s health innovation ecosystem. With cornerstone investments from Eurazeo, Bpifrance, and CSL, and following successful exits from the Biofund III portfolio, the new fund demonstrates investor confidence in Kurma’s approach to healthcare innovation.
For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.